Pacific Biosciences of California, Inc. (PACB) Earnings History
Annual and quarterly earnings data from 2008 to 2025
Loading earnings history...
PACB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PACB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 31.7% | -348.5% | -341.5% |
| 2024 | 24.2% | -308.0% | -201.2% |
| 2023 | 26.3% | -166.8% | -153.0% |
| 2022 | 38.2% | -239.4% | -244.9% |
| 2021 | 45.1% | -161.2% | -138.9% |
Download Data
Export PACB earnings history in CSV or JSON format
Free sign-in required to download data
Pacific Biosciences of California, Inc. (PACB) Earnings Overview
As of May 8, 2026, Pacific Biosciences of California, Inc. (PACB) reported trailing twelve-month net income of -$546M, reflecting -70.1% year-over-year growth. The company earned $-1.81 per diluted share over the past four quarters, with a net profit margin of -341.5%.
Looking at the long-term picture, PACB's historical earnings data spans multiple years. The company achieved its highest annual net income of $29M in fiscal 2020.
Pacific Biosciences of California, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ILMN ($853M net income, 19.6% margin), BFLY (-$76M net income, -79.0% margin), CDNA (-$8M net income, -5.6% margin), PACB has room to improve margins relative to the peer group. Compare PACB vs ILMN →
PACB Earnings vs Peers
Earnings metrics vs comparable public companies
PACB Historical Earnings Data (2008–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$546M | -76.3% | -$558M | $-1.82 | -341.5% | -348.5% |
| 2024 | -$310M | -1.0% | -$474M | $-1.07 | -201.2% | -308.0% |
| 2023 | -$307M | +2.4% | -$334M | $-1.21 | -153.0% | -166.8% |
| 2022 | -$314M | -73.4% | -$307M | $-1.40 | -244.9% | -239.4% |
| 2021 | -$181M | -716.3% | -$210M | $-0.89 | -138.9% | -161.2% |
| 2020 | $29M | +134.9% | -$104M | $0.17 | 37.3% | -132.3% |
| 2019 | -$84M | +18.0% | -$101M | $-0.51 | -92.6% | -110.6% |
| 2018 | -$103M | -11.3% | -$101M | $-0.76 | -130.4% | -128.4% |
| 2017 | -$92M | -24.0% | -$90M | $-0.87 | -98.6% | -96.1% |
| 2016 | -$74M | -134.7% | -$71M | $-0.83 | -82.0% | -78.5% |
See PACB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PACB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PACB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPACB — Frequently Asked Questions
Quick answers to the most common questions about buying PACB stock.
Is PACB growing earnings?
PACB EPS fell to $-1.81, with earnings declining -70.1%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-546M.
What are PACB's profit margins?
Pacific Biosciences of California, Inc. net margin is -341.5%, with operating margin at -348.5%. Below-average margins reflect competitive or cost pressures.
How consistent are PACB's earnings?
PACB earnings data spans 2008-2025. The declining earnings trend is -70.1% YoY. Historical data enables comparison across business cycles.